You are here:
Some of our top research stories from the past year.
A new study has found that increasing calcium and protein intake in Australian aged care residents could save the healthcare system up to $66 million a year.
Melbourne researchers have designed a single drug that delivers a lethal ‘one-two’ punch to several types of blood cancer in preclinical studies and could lead to improved treatments.
An Australian register set up to help pregnant women with epilepsy has helped dramatically reduce the number of stillbirths and birth defects such as spina bifida, and the resulting costs to the community, a new Monash University study reveals.
A new study involving 200 educators from 22 countries will pave the way for improvements in pharmacology education globally.
Cutting-edge technology has revealed new and unprecedented information of how “allosteric modulators” work at a major target for notoriously difficult-to-treat psychiatric disorders associated with cognitive deficits.
Monash University has published a new study to determine the current attitudes of Australian representatives across major governance and advocacy groups towards using psychedelic agents to treat mental health conditions.
Drug discovery researchers from Monash University have uncovered new and unexpected information about ‘xanomeline’, a potential-first-in class drug currently progressing through Phase III clinical trials for the treatment of patients with schizophrenia.
A new Australian study by Monash University has compared two classes of drugs used to treat type 2 diabetes and found that one of the two classes is associated with a greater reduction of major adverse cardiovascular events in men than in women.
A new study by Monash University has found Australians living with dementia are potentially being overtreated for diabetes, despite clinical guidelines recommending a less stringent approach to treating diabetes for people with coexisting dementia.
A preclinical study led by Monash University has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular carcinoma.
A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne.
Discoveries with real-world impact.
Monash's CSIRO acquisition.
Return to issue home page.
